Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL3038498 Target Snapshot

Keap1/Nrf2 · PROTEIN-PROTEIN INTERACTION · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
1,869Compounds
247Assays
4Approved Drugs
1,806.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Keap1/Nrf2 shows late clinical disease relevance led by Autosomal dominant polycystic kidney disease. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt Q16236. Start with Autosomal dominant polycystic kidney disease, then reuse UniProt Q16236 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with Autosomal dominant polycystic kidney disease, then reuse UniProt Q16236 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 1 linked drug
Open source guide
Disease program
Autosomal dominant polycystic kidney disease

Keap1/Nrf2 shows late clinical disease relevance led by Autosomal dominant polycystic kidney disease. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with Autosomal dominant polycystic kidney disease because it currently carries late clinical support. Linked drugs include BARDOXOLONE METHYL. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Late clinical Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Keap1/Nrf2 as ChEMBL target CHEMBL3038498, mapped to UniProt Q16236. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Keap1/Nrf2
PROTEIN-PROTEIN INTERACTION · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL3038498
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
Q16236
Nuclear factor erythroid 2-related factor 2
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Keap1/Nrf2 is the right protein anchor across sources, using UniProt Q16236 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why Autosomal dominant polycystic kidney disease is currently framed as late clinical support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameKeap1/Nrf2
Target TypePROTEIN-PROTEIN INTERACTION
OrganismHomo sapiens
UniProtQ16236
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelNuclear factor erythroid 2-related factor 2
UniProt AccessionQ16236
Component TypeProtein
Sequence Length605 aa

Nuclear factor erythroid 2-related factor 2

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Keap1/Nrf2, mapped to UniProt Q16236. ChEMBL maps the protein component as Nuclear factor erythroid 2-related factor 2. Sequence length is 605 aa.

Mapped IDQ16236
Review nameKeap1/Nrf2
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Late clinical Open Targets-ready proxy

Keap1/Nrf2 shows late clinical disease relevance led by Autosomal dominant polycystic kidney disease. 5 more disease programs remain visible in the same review block.

Late clinical Phase III
Autosomal dominant polycystic kidney disease
1 linked drug · 1 direct · 1 efficacy
Linked drugBARDOXOLONE METHYL
Late clinical Phase III
diabetic nephropathy
1 linked drug · 1 direct · 1 efficacy
Linked drugBARDOXOLONE METHYL
Late clinical Phase III
pulmonary arterial hypertension
1 linked drug · 1 direct · 1 efficacy
Linked drugBARDOXOLONE METHYL
Late clinical Phase III
pulmonary hypertension
1 linked drug · 1 direct · 1 efficacy
Linked drugBARDOXOLONE METHYL
Clinical signal Phase II
Alport syndrome
1 linked drug · 1 direct · 1 efficacy
Linked drugBARDOXOLONE METHYL
Clinical signal Phase II
chronic kidney disease
1 linked drug · 1 direct · 1 efficacy
Linked drugBARDOXOLONE METHYL
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with Autosomal dominant polycystic kidney disease because it currently carries late clinical support. Linked drugs include BARDOXOLONE METHYL. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseAutosomal dominant polycystic kidney disease
Strongest levelLate clinical
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

4
Approved
1
Phase III
Assay Mix

Activity Type Distribution

IC50838.0
KI165.0
EC5074.0
KD729.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5759229 11.0 Kd 0.01 Preclinical
CHEMBL5886931 10.62 Kd 0.024 Preclinical
CHEMBL6052915 10.39 Kd 0.041 Preclinical
CHEMBL6036229 10.38 Kd 0.042 Preclinical
CHEMBL5945962 10.1 Kd 0.079 Preclinical
CHEMBL5920236 10.09 Kd 0.081 Preclinical
CHEMBL5997320 10.09 Kd 0.081 Preclinical
CHEMBL5893955 10.05 Kd 0.089 Preclinical
CHEMBL5996288 9.92 Kd 0.12 Preclinical
CHEMBL5915606 9.9 Kd 0.127 Preclinical
Distribution

pChEMBL Value Distribution

127
5.0
154
5.5
184
6.0
92
6.5
260
7.0
53
7.5
39
8.0
58
8.5
6
9.0
10
9.5
pChEMBL
Assay Landscape

Assay Landscape

247
Total Assays
1,061
Tested Compounds
1
Assay Types
Binding — 247 assays, 1,061 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 170 240 5.7
protein format 71 606 6.3
assay format 3 215 7.2
tissue-based format 2 0 —
biochemical format 1 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine